[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561047":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":22,"studyPopulation":23,"armGroups":16,"interventions":24,"overallOfficials":28,"centralContacts":32,"locations":38,"responsibleParty":58,"collaborators":16,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":16,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":16,"enrollmentInfo":71,"targetDuration":16,"studyType":74,"phases":16,"briefSummary":75,"conditions":76,"keywords":80,"overallStatus":41,"whyStopped":16,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Shanghai Changzheng Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":16},[9],{"measure":10,"description":11,"timeFrame":12},"Number of Participants Who developed glucose metabolic disorders(pre-diabetes and diabetes mellitus)","The diagnosis of glucose disorders should be made applying criteria of the American Diabetes Association.","From enrollment to five years after the end of the surgery",[14,17],{"measure":15,"description":16,"timeFrame":12},"Overall Survival",null,{"measure":18,"description":16,"timeFrame":12},"Disease-Free Survival",{"allocation":16,"interventionModel":16,"interventionModelDescription":16,"primaryPurpose":16,"observationalModel":20,"timePerspective":21,"maskingInfo":16},"COHORT","PROSPECTIVE","Investigators will prospectively collect data from patients with pancreatic cancer after surgery in participant centers.","patients with pancreatic cancer after pancreatic surgery",[25],{"type":26,"name":27,"description":27,"armGroupLabels":16,"otherNames":16},"DIAGNOSTIC_TEST","All enrolled subjects completed dynamic blood glucose monitoring to obtain continuous peripheral blood glucose data.",[29],{"name":30,"affiliation":5,"role":31},"tuo Li, Prof.","STUDY_DIRECTOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":16,"email":37},"Tuo Li, Doctor","CONTACT","86-13918507887","dr.lituo@smmu.edu.cn",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Changzheng Hospital","RECRUITING","Shanghai","Shanghai Municipality","200003","China","CN",{"type":48,"coordinates":49},"Point",[50,51],121.45806,31.22222,{"lat":51,"lon":50},[54],{"name":55,"role":35,"phone":56,"phoneExt":16,"email":57},"tuo li","13918507887","zoe_leeto@hotmail.com",{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":16,"oldOrganization":16},"PRINCIPAL_INVESTIGATOR","Tuo Li, MD","Deputy Director","100561047","pancreatic-cancer-and-diabetes-mellitus-100561047",false,"NCT06585072","Pancreatic Cancer and Diabetes Mellitus","Prospective Cohort Study on Endo-Exdo Secretory Function Alterations and All-round Outcomes After Pancreatic Cancer","Inclusion Criteria:\n\n1\\. male or female Chinese subjects; 2. Age ≥ 18 years; 3. patients with pancreatic cancer who are proposed to undergo pancreatectomy by pancreaticobiliary surgery at our hospital; 4. those who voluntarily completed the Pancreatobiliary Surgery Cohort Study and signed the informed consent; 5. those who have completed and banked serum and pathological specimens at our hospital.\n\n\\-\n\nExclusion Criteria:\n\n1\\. those with a previous history of comorbid diabetes mellitus or pre-diabetes mellitus, or preoperative HbA1C ≥ 6.0% or fasting blood glucose ≥ 6.1 mmol\u002Fl; 2. those with positive islet-associated antibodies 3. those with the presence of medications, endocrine disease exposures that can lead to a risk of secondary diabetes; 4. pregnant or nursing women; 5. Cognitive impairment or other reasons for failing to sign the informed consent form.\n\n\\-","ALL","18 Years",{"count":72,"type":73},150,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about post-surgery of pancreatic cancer diabetes mellitus.The main questions it aims to answer are:\n\n1. Are the incident rates of glucose metabolic disorders (pre-diabetes and diabetes mellitus) after pancreatic cancer of different etiologies the same?\n2. Are alterations in endocrine and exdocrine secretory function in patients with pancreatic surgery associated with all-round outcomes? All patients with pancreatic surgery have been given the standardized treatment for the condition.\n\nThe reasearchers will summarize the incident rates of glucose metabolic disorders (pre-diabetes and diabetes mellitus) during different surgical procedures to explore the association between alternations in endocrine and exdocrine secrectory function and all-round outcomes.",[77,78,79],"Pancreatic Cancer","Surgery","Diabetes Mellitus",[77,78,79,81],"Risk factor","2025-06-26",{"date":84,"type":85},"2025-07-01","ACTUAL",{"date":87,"type":85},"2025-01-03",{"date":89,"type":73},"2026-09-01",{"name":5,"class":6},1]